Silencing MFN2 Drives WNT/β-catenin Nucleation to Reduce Sorafenib Sensitivity in Hepatocellular Carcinoma Cells

Abstract

Objective

Mitofusin-2 (MFN2) is a mitochondrial membrane protein that plays a critical role in regulating mitochondrial fusion and cellular metabolism. To further elucidate the impact of MFN2, this study aimed to investigate its significance on hepatocellular carcinoma (HCC) cell function and its potential role in mediating chemosensitivity.

Methods

This study investigated the effects of silencing and overexpressing MFN2 on the survival, proliferation, invasion and migration abilities, and sorafenib resistance of MHCC97-L HCC cells. Additional experiments were conducted using XAV939 (a β-catenin inhibitor) and HLY78 (a β-catenin activator) to further validate these findings.

Results

Silencing MFN2 significantly promoted the survival and proliferation of MHCC97-L cells, enhanced their invasion and migration capacities, increased the IC₅₀ of sorafenib, reduced the percentage of TUNEL-positive cells, and decreased the expression of proapoptotic proteins. Additionally, silencing MFN2 markedly induced the nuclear translocation of β-catenin, increased β-catenin acetylation levels and enhanced the expression of the downstream regulatory proteins Snail1 and Vimentin while inhibiting E-cadherin expression. Conversely, overexpressing MFN2 reversed the effects observed in MHCC97-L cells mentioned above. The results confirmed that silencing MFN2 activated the β-catenin/epithelial-mesenchymal transition (EMT) pathway and reduced the sensitivity of cells to sorafenib, which could be reversed by XAV939 treatment. Conversely, overexpression of MFN2 inhibited the β-catenin/EMT pathway and increased the sensitivity of cells to sorafenib, which could be altered by HLY78.

Conclusion

Low expression of MFN2 in HCC cells promotes the nuclear translocation of β-catenin, thereby activating the EMT pathway and mediating resistance to sorafenib.

References

[1] HuP, ZongB, ChenQ, et al.. Microtubule-associated protein 4 promotes epithelial mesenchymal transition in hepatocellular cancer cells by regulating GSK3 β/β-catenin pathway. Heliyon, 2023, 9(3): e14309

[2] TangW, ChenZ, ZhangW, et al.. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther, 2020, 5(1): 87

[3] PangG, XieQ, YaoJ. Mitofusin 2 inhibits bladder cancer cell proliferation and invasion via the Wnt/β-catenin pathway. Oncol Lett, 2019, 18(3): 2434-2442

[4] YouMH, JeonMJ, KimSR, et al.. Mitofusin-2 modulates the epithelial to mesenchymal transition in thyroid cancer progression. Sci Rep, 2021, 11(1): 2054

[5] AhnSY, SongJ, KimYC, et al.. Mitofusin-2 Promotes the Epithelial-Mesenchymal Transition-Induced Cervical Cancer Progression. Immune Netw, 2021, 21(4): e30

[6] WuY, ZhouD, XuX, et al.. Clinical significance of mitofusin-2 and its signaling pathways in hepatocellular carcinoma. World J Surg Oncol, 2016, 14(1): 179

[7] WangW, LuJ, ZhuF, et al.. Pro-apoptotic and anti-proliferative effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells. Med Oncol, 2012, 29(1): 70-76

[8] ChenZ, LinZ, YuJ, et al.. Mitofusin-2 Restrains Hepatic Stellate Cells’ Proliferation via PI3K/Akt Signaling Pathway and Inhibits Liver Fibrosis in Rats. J Healthc Eng, 2022, 2022: 6731335

[9] ZhangH, TangQF, SunMY, et al.. ARHGAP9 suppresses the migration and invasion of hepatocellular carcinoma cells through upregulating FOXJ2/E-cadherin. Cell Death Dis, 2018, 9(9): 916

[10] LuY, ShenH, HuangW, et al.. Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance. Cell Death Discov, 2021, 7(1): 359

[11] YuX, LiZ, BaiR, et al.. Transcription factor 3 binds to sirtuin 1 to activate the Wnt/β-catenin signaling in cervical cancer. Bioengineered, 2022, 13(5): 12516-12531

[12] YuJ, GeZ, ChenS, et al.. miR-26a-5p Suppresses Wnt/β-Catenin Signaling Pathway by Inhibiting DNMT3A-Mediated SFRP1 Methylation and Inhibits Cancer Stem Cell-Like Properties of NSCLC. Dis Markers, 2022, 2022: 7926483

[13] CaiY, LyuT, LiH, et al.. LncRNA CEBPA-DT promotes liver cancer metastasis through DDR2/β-catenin activation by interacting with hnRNPC. J Exp Clin Cancer Res, 2022, 41(1): 335

[14] LeungHW, LeungC, LauEY, et al.. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma. Cancer Res, 2021, 81(12): 3229-3240

[15] DengL, YiS, YinX, et al.. MFN2 knockdown promotes osteogenic differentiation of iPSC-MSCs through aerobic glycolysis mediated by the Wnt/β-catenin signaling pathway. Stem Cell Res Ther, 2022, 13(1): 162

[16] KimYM, KrantzS, JambusariaA, et al.. Mitofusin-2 stabilizes adherens junctions and suppresses endothelial inflammation via modulation of β-catenin signaling. Nat Commun, 2021, 12(1): 2736

[17] LiuJ, XiaoQ, XiaoJ, et al.. Wnt/β-catenin signaling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther, 2022, 7(1): 3

[18] XiongW, ZhangL, LiuH, et al.. E2-mediated EMT by activation of β-catenin/Snail signaling during the development of ovarian endometriosis. J Cell Mol Med, 2019, 23(12): 8035-8045

[19] GillesC, PoletteM, MestdagtM, et al.. Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res, 2003, 63(10): 2658-2664

[20] CanoA, Pérez-MorenoMA, RodrigoI, et al.. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol, 2000, 2(2): 76-83

[21] WangSS, YouX, LiuXS, et al.. SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. iScience, 2023, 26(7): 106994

[22] ShiY, WangJ, HuangG, et al.. A novel epithelial-mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma. Hepatol Int, 2022, 16(4): 906-917